Drug intelligence / Profile preview

APH-1403

Development stage: Preclinical
Lead developer: Aphios
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

APH-1403 is a nanotechnology-based oral therapeutic being developed by Aphios Corporation for the treatment of multiple sclerosis (MS). It consists of a small-molecule PPAR-γ (Peroxisome Proliferator-Activated Receptor gamma) agonist encapsulated in biodegradable polymer nanospheres using proprietary SuperFluids technology. By activating the PPAR-γ pathway, APH-1403 exerts anti-inflammatory and neuroprotective effects. The nanoformulation is designed to improve oral bioavailability and bypass first-pass metabolism, aiming to treat MS flares and slow disability progression in primary and secondary progressive MS.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on APH-1403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-1403.

Explore the full profile